Welcome back to another episode of “Health Breakthroughs,” where we explore the latest in medical innovation. Today, we’re diving into something that could be a game-changer for millions of people living with type 2 diabetes – a new outpatient endoscopic treatment called ReCET.

Rewiring the Gut

Type 2 diabetes has traditionally been managed with medications – pills, injections, insulin – all targeting symptoms. But what if we could go to the source of the problem and start fixing things upstream?

That’s exactly what ReCET – short for Re-cellularization via Electroporation Therapy – aims to do. It’s a cutting-edge, non-thermal endoscopic procedure that targets the duodenum, the first part of the small intestine. And no, it doesn’t burn or cut – it uses pulsed electrical fields to regenerate the tissue.

So how does it work?

* The entire procedure currently takes 30 to 60 minutes, but the goal is to bring it down to just 20 minutes in the future.

* It’s outpatient, meaning you can go home the same day.

* It’s designed to restore healthy signaling in the gut, which influences how your body manages sugar, insulin, and fat storage.

Dr. Barham Abu Dayyeh, who presented this at Digestive Disease Week 2025, describes the duodenum as the “conductor of the metabolic orchestra.”

Right now, diabetes treatments focus on fixing individual instruments – like the pancreas or liver. But what if the real solution is to get the conductor back in rhythm?

Thanks for reading Bariatric Journal! This post is public so feel free to share it.

What did the results show?

In a recent clinical trial called REGENT-1, involving 51 people with type 2 diabetes:

* HbA1c dropped significantly at 12 and 48 weeks – up to 1.7 percentage points in some patients.

* Insulin sensitivity skyrocketed, improving by nearly 5-fold.

* Beta-cell function – how well your pancreas makes insulin – also improved.

* Weight loss occurred across all groups, especially those receiving higher energy doses.

* No serious side effects linked to the device or the procedure.

And here’s a shocker:

Compared to medications like semaglutide or tirzepatide, ReCET showed better improvement in insulin sensitivity and overall metabolic function in some categories. That’s impressive.

What’s the vision for the future?

Dr. Abu Dayyeh sees this becoming as routine as a colonoscopy. Primary care doctors or endocrinologists might refer patients to a GI specialist, who performs the procedure and sends them back with a simpler treatment plan – maybe even fewer meds or no insulin at all.

Importantly, ReCET isn’t meant to replace medication but to enhance and complement it – especially for those early in their diabetes journey or struggling with control.

What’s next?

* A large randomized, sham-controlled clinical trial is already underway, with results expected by late 2026.

* If successful, ReCET could reshape how we think about type 2 diabetes – not just as a chronic condition to manage, but one we can possibly reverse or modify at its root.

Final Thoughts:

We’re entering an era where minimally invasive gut-based therapies might rival traditional medications. ReCET offers real hope – not just to lower blood sugar, but to tackle the deeper dysfunction behind type 2 diabetes.

Stay tuned, because this is just the beginning of a fascinating new chapter in metabolic health.

Thanks for listening. Until next time, stay healthy and stay curious.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit drmuratustun.substack.com